Physician profile
Michael Delaney
NPI 1174905905
$1,650.30
in general payments reported to CMS, 2019-2025
24 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.80 · 2021: $250 · 2022: $143 · 2023: $115 · 2024: $692 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.97 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.00 | 2020-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $247.21 | 2021-2024 | Arexvy |
| Astrazeneca Pharmaceuticals Lp | $206.74 | 2023-2025 | Breztri, Farxiga, Nexium |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.44 | 2020-2024 | Ofev, Jardiance |
| Novo Nordisk INC | $99.24 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $84.80 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $60.41 | 2022-2025 | Zepbound, Jardiance |
| Amgen INC. | $57.81 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $48.89 | 2025 | |
| Gilead Sciences, INC. | $27.95 | 2025 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.72 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $25.90 | 2021-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $24.62 | 2022 | |
| Alkermes, INC. | $23.55 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.42 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.18 | 2024 | Sublocade |
| Radius Health, INC. | $20.21 | 2024 | Tymlos |
| Amarin Pharma, INC. | $19.19 | 2020 | |
| Abbott Laboratories | $17.57 | 2025 | Esprit |
| Antares Pharma, INC. | $16.75 | 2023 | Tlando, Xyosted, Nocdurna |
| Mylan Specialty L.P. | $16.22 | 2022 | |
| Merck Sharp & Dohme LLC | $16.12 | 2024 | Proquad, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2025 | Eohilia |
| Exact Sciences Corporation | $13.60 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Delaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.